William Blair initiated coverage on Lucira Health
$LHDX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
William Blair initiated coverage of Lucira Health with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
Lab-quality results for both COVID-19 and Flu now available at home from one single testCOVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access time-sensitive prescription treatment optionsLucira's COVID-19 & Flu Home Test demonstrated similar performance for COVID-19, Flu A and Flu B in head-to-head comparison study with highly sensitive lab-based PCR testsLucira seeks a strategic or financial partner for resumption of manufacturing and development of additional home diagnostic products EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health" or "Lucira"), a medical technology company,
EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company, announced today that it has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, while continuing to support its customers during the Chapter 11 process. Lucira Health grew rapidly over the past several years as the COVID-19 pandemic spread throughout the world. Demand for the Company's COVID-19 test kits surged and the Company p
New partnership enables a free Sesame telehealth consultation with purchase of a Lucira at-home COVID-19 test, providing a full test-to-treat experience from the comfort of home, within two hours NEW YORK , Jan. 5, 2023 /PRNewswire/ -- Sesame, the company building a radically new healthcare system for uninsured Americans and those with high-deductible plans, and Lucira Health, Inc. ("Lucira Health" or "Lucira") today announced their national partnership to increase access to high-quality, convenient and affordable COVID-19 testing and treatment. Via Lucira Connect, a recently-launched virtual care platform, patients who purchase Lucira's COVID-19 Test can now easily learn about treatment opt
William Blair downgraded Lucira Health from Market Outperform to Market Perform
BofA Securities downgraded Lucira Health from Neutral to Underperform and set a new price target of $9.00
William Blair initiated coverage of Lucira Health with a rating of Outperform
15-12G - Lucira Health, Inc. (0001652724) (Filer)
8-K - Lucira Health, Inc. (0001652724) (Filer)
NT 10-Q - Lucira Health, Inc. (0001652724) (Filer)
EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the third quarter ended September 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $34.4 million for the third quarter of 2022, an increase of 130% over the third quarter of 2021.Executed a marketing agreement with Pfizer to increase awareness of the risks of COVID-19 and the availability of treatment. Partnered with telehealth marketplace, Sesame Care
EMERYVILLE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients with providers, today announced that the company will report third quarter 2022 financial results on, Monday, November 14th, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsInvestors interested in listening to the conference call should reg
EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the second quarter ended June 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $26.1 million for the second quarter of 2022, an increase of 110% over the second quarter of 2021Received regulatory approval in Canada for the COVID-19 & Flu test with Self Test at Home indication and a full exemption by the New Zealand Ministry of Health for COVID-19 testSc
SC 13D/A - Lucira Health, Inc. (0001652724) (Subject)